Development and evaluation of nanoemulsion and microsuspension formulations of curcuminoids for lung delivery with a novel approach to understanding the aerosol performance of nanoparticles

Abstract

Extensive research has demonstrated the potential effectiveness of curcumin against various diseases, including asthma and cancers. However, few studies have used liquid-based vehicles in the preparation of curcumin formulations. Therefore, the current study proposed the use of nanoemulsion and microsuspension formulations to prepare nebulised curcuminoid for lung delivery. Furthermore, this work expressed a new approach to understanding the aerosol performance of nanoparticles compared to microsuspension formulations. The genotoxicity of the formulations was also assessed. Curcuminoid nanoemulsion formulations were prepared in three concentrations (100, 250 and 500 µg/ml) using limonene and oleic acid as oil phases, while microsuspension solutions were prepared by suspending curcuminoid particles in isotonic solution (saline solution) of 0.02% Tween 80. The average fine particle fraction (FPF) and mass median aerodynamic diameter (MMAD) of the nebulised microsuspension formulations ranged from 26% and 7.1 µm to 40% and 5.7 µm, for 1000 µg/ml and 100 µg/ml respectively. In a comparison of the low and high drug concentrations of the nebulised nanoemulsion, the average FPF and MMAD of the nebulised nanoemulsion formulations prepared with limonene oil ranged from 50% and 4.6 µm to 45% and 5.6 µm, respectively; whereas the FPF and MMAD of the nebulised nanoemulsion prepared with oleic acid oil ranged from 46% and 4.9 µm to 44% and 5.6 µm, respectively. The aerosol performance of the microsuspension formulations were concentration dependent, while the nanoemulsion formulations did not appear to be dependent on the curcuminoids concentration. The performance and genotoxicity results of the formulations suggest the suitability of these preparations for further inhalation studies in animals.

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

“…Genotoxicity using Comet assay showed that the developed NEs are nontoxic at the tested curcuminoid doses suggesting the safety and suitability of the developed NEs. The authors recommend further pre-clinical and clinical studies [ 120 ]. However, additional cytotoxicity evaluation and in vitro release study are also essential in such formulations.…”

Safety and efficacy of turmeric extract, turmeric oil, turmeric oleoresin and turmeric tincture from Curcuma longa L. rhizome when used as sensory additives in feed for all animal species

“…Experimental test system (aim of the study) Test substance/Relevance Exposure conditions Result Comments Relevance of the resultsAyoub et al. () Lymphocytes Nanoemulsion formulations of curcuminoids, prepared using limonene and oleic acid as oil phases.Microsuspension solutions, prepared by suspending curcuminoid particles in isotonic solution (saline solution) of 0.02% Tween 80 (surfactant) Relevance: limited Nanoemulsion tested at three curcumin concentrations (100, 250 and 500 μg/mL)Incubation 30 min at 37 °CComputerised image system to measure Comet parameters, % olive tail moment used for statisticsThe DNA damage observed for six nanoemulsion formulations was lower than that of the negative control indicating some protective effect of the curcumin nanoemulsions Negative Test as reported by Ostling and Johanson, 1984, Singh et al. 1988 and Olive et al., 1990 Low (as in vitro comet)Blasiak et al.…”

Demethoxycurcumin Promotes Macrophage Cell Population and Phagocytosis in WEHI-3 Cell-generated Leukemia BALB/c MiceIn Vivo

“…Curcuminoids consist of at least three major compounds, including curcumin, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC). DMC is one of the main bioactive components of curcuminoids (11), and it is more stable in the blood than other curcuminoids (12). DMC suppressed prostate cancer cell migration and invasion (13) and induced DNA damage and apoptosis in lung cancer cells (14).…”